Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia

References

• American Cancer Society. Cancer facts and figures 2016. Atlanta (GA): American Cancer Society; 2016.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. Childhood cancer by the ICCC. SEER cancer statistics review, 1975–2010. Bethesda (MD): National Cancer Institute; 2013.
   Google Scholar
• Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–1552.
   PubMed Web of Science ®Google Scholar
• Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–2948.
   PubMed Web of Science ®Google Scholar
• Douer D. Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Pract Res Clin Haematol. 2008;21:647–658.
   PubMed Web of Science ®Google Scholar
• Boissel N, Sender LS. Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: a focus on asparaginase. J Adolesc Young Adult Oncol. 2015;4:118–128.
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc MF, Lhéritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774–780.
   PubMed Web of Science ®Google Scholar
• de Bont JM, Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18:2032–2035.
   PubMed Web of Science ®Google Scholar
• Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007;48:254–261.
   PubMed Web of Science ®Google Scholar
• Testi AM, Valsecchi MG, Conter V, et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood. 2004;104:1954.
   Web of Science ®Google Scholar
• Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children’s cancer group and cancer and leukemia group B studies. Blood. 2008;112:1646–1654.
   PubMed Web of Science ®Google Scholar
• Jaffe N, Traggis D, Das L, et al. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res. 1971;31:942–949.
   PubMed Web of Science ®Google Scholar
• Capizzi RL, Bertino JR, Skeel RT, et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med. 1971;74:893–901.
   PubMed Web of Science ®Google Scholar
• Tallal L, Tan C, Oettgen H, et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer. 1970;25:306–320.
   PubMedGoogle Scholar
• Appel IM, den Boer ML, Meijerink JP, et al. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood. 2006;107:4244–4249.
   PubMed Web of Science ®Google Scholar
• Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22:1665–1679.
   PubMed Web of Science ®Google Scholar
• Nesbit ME, Ertel I, Hammond GD. L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form childrens cancer study group. Cancer Treat Rep. 1981;65:101–107.
   PubMedGoogle Scholar
• Sutow WW, Garcia F, Starling KA, et al. L-asparaginase therapy in children with advanced leukemia. The Southwest cancer chemotherapy study group. Cancer. 1971;28:819–824.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the children’s oncology group. Blood. 2008;111:2548–2555.
   PubMed Web of Science ®Google Scholar
• Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663–1671.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood. 2001;97:1211–1218.
   PubMed Web of Science ®Google Scholar
• Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood. 2000;96:1709–1715.
   PubMed Web of Science ®Google Scholar
• Broome JD. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature. 1961;191:1114–1115.
   Web of Science ®Google Scholar
• Ho DH, Whitecar JP, Jr, Luce JK, et al. L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow. Cancer Res. 1970;30:466–472.
   PubMed Web of Science ®Google Scholar
• Onuma T, Waligunda J, Holland JF. Amino acid requirements in vitro of human leukemic cells. Cancer Res. 1971;31:1640–1644.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B study 9511. Blood. 2007;109:4164–4167.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54:199–205.
   PubMed Web of Science ®Google Scholar
• Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015;56:2273–2280.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study – Dana-Farber cancer institute ALL consortium protocol 00-01. J Clin Oncol. 2013;31:1202–1210.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEG asparaginase and erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123:2026–2033.
   PubMed Web of Science ®Google Scholar
• Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children’s cancer group study CCG-1961. J Pediatr Hematol Oncol. 2004;26:217–226.
   PubMed Web of Science ®Google Scholar
• Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med. 1963;118:99–120.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28:97–113.
   PubMed Web of Science ®Google Scholar
• Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005;130:860–868.
   PubMed Web of Science ®Google Scholar
• Neuman RE, McCoy TA. Dual requirement of Walker carcinosarcoma 256 in vitro for asparagine and glutamine. Science. 1956;124:124–125.
   PubMed Web of Science ®Google Scholar
• Haley EE, Fischer GA, Welch AD. The requirement for L-asparagine of mouse leukemia cells L5178Y in culture. Cancer Res. 1961;21:532–536.
   PubMed Web of Science ®Google Scholar
• Avramis VI. Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res. 2012;32:2423–2437.
   PubMed Web of Science ®Google Scholar
• Hutson RG, Kitoh T, Moraga Amador DA, et al. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol. 1997;272:C1691–C1699.
   PubMed Web of Science ®Google Scholar
• Iwamoto S, Mihara K, Downing JR, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007;117:1049–1057.
   PubMed Web of Science ®Google Scholar
• Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621–629.
   PubMed Web of Science ®Google Scholar
• Keding R. 2012. RE: Discontinuation of Elspar®, (asparaginase for injection) 10,000 IU. [Internet]. Deerfield, IL: Lundbeck LLC. August 2012; [cited 2017 Apr 27]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM321556.pdf
   Google Scholar
• Zalewska-Szewczyk B, Gach A, Wyka K, et al. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med. 2009;9:113–116.
   PubMed Web of Science ®Google Scholar
• Erwinaze (asparaginase Erwinia chrysanthemi) [prescribing information]. Palo Alto (CA): Jazz Pharmaceuticals, Inc.; 2016.
   Google Scholar
• Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117:238–249.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed. 2006;1:241–254.
   PubMed Web of Science ®Google Scholar
• Haskell CM, Canellos GP. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochem Pharmacol. 1969;18:2578–2580.
   PubMed Web of Science ®Google Scholar
• Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J. 2001;357:321–328.
   PubMed Web of Science ®Google Scholar
• Stams WA, den Boer ML, Holleman A, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood. 2005;105:4223–4225.
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Andrzejewski W, et al. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007;48:931–936.
   PubMed Web of Science ®Google Scholar
• Panosyan EH, Grigoryan RS, Avramis IA, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res. 2004;24:1121–1125.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44:367–393.
   PubMed Web of Science ®Google Scholar
• Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996;32A:1544–1550.
   PubMed Web of Science ®Google Scholar
• Jarrar M, Gaynon PS, Periclou AP, et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a children’s oncology group study (CCG-1941). Pediatr Blood Cancer. 2006;47:141–146.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Lorenson MY, Whitin JC, et al. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res. 1991;51:6568–6573.
   PubMed Web of Science ®Google Scholar
• Gentili D, Zucchetti M, Conter V, et al. Determination of L-asparagine in biological samples in the presence of L-asparaginase. J Chromatogr B, Biomed Appl. 1994;657:47–52.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109:2744–2750.
   PubMed Web of Science ®Google Scholar
• Grigoryan RS, Panosyan EH, Seibel NL, et al. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo. 2004;18:107–112.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Kreissman S, Coppola DJ, et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1999;21:6–12.
   PubMed Web of Science ®Google Scholar
• Chan WK, Lorenzi PL, Anishkin A, et al. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. Blood. 2014;123:3596–3606.
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from children’s oncology group study AALL07P4. J Clin Oncol. 2014;32:3874–3882.
   PubMed Web of Science ®Google Scholar
• Rizzari C, Zucchetti M, Conter V, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving I.M. or I.V. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol. 2000;11:189–193.
   PubMed Web of Science ®Google Scholar
• Pieters R, Appel I, Kuehnel HJ, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood. 2008;112:4832–4838.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Schroder H, Jakobsen P, et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol. 2001;52:433–437.
   PubMed Web of Science ®Google Scholar
• Schore RJ, Devidas M, Bleyer A, etet al. Plasma asparaginase activity and asparagine depletion in patients with acute lymphoblastic leukemia (ALL) treated with pegaspargase (SS-PEG E. coli L-asparaginase): results from Children’s Oncology Group (COG) study AALL07P4. J Clin Oncol. 2016;34(suppl):10508.
   Web of Science ®Google Scholar
• Riccardi R, Holcenberg JS, Glaubiger DL, et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 1981;41:4554–4558.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children’s cancer group study. Blood. 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006;91:24–31.
   PubMed Web of Science ®Google Scholar
• van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101:279–285.
   PubMed Web of Science ®Google Scholar
• Vieira Pinheiro JP, Ahlke E, Nowak GU, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol. 1999;104:313–320.
   PubMed Web of Science ®Google Scholar
• Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43:5601–5607.
   PubMed Web of Science ®Google Scholar
• Sallan SE, Gelber RD, Kimball V, et al. More is better! update of Dana-Farber cancer institute/children’s hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus. 1990;33:459–466.
   PubMedGoogle Scholar
• Ortega JA, Nesbit ME, Donaldson MH, et al. L-asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 1977;37:535–540.
   PubMed Web of Science ®Google Scholar
• Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a pediatric oncology group study. Leukemia. 1999;13:335–342.
   PubMed Web of Science ®Google Scholar
• Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:7161–7167.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Jakobsen P, Schroder H, et al. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemother Pharmacol. 2001;48:77–82.
   PubMed Web of Science ®Google Scholar
• Schrey D, Borghorst S, Lanvers-Kaminsky C, et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr Blood Cancer. 2010;54:952–958.
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18:1525–1532.
   PubMed Web of Science ®Google Scholar
• Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood. 2012;119:1658–1664.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780–1786.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Kirov II, Dreyer ZE, et al. Activity and toxicity of intravenous Erwinia asparaginase following allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63:228–233.
   PubMed Web of Science ®Google Scholar
• Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the children’s oncology group. Blood. 2013;122:507–514.
   PubMed Web of Science ®Google Scholar
• Bleyer A, Asselin BL, Koontz SE, et al. Clinical application of asparaginase activity levels following treatment with pegaspargase. Pediatr Blood Cancer. 2015;62:1102–1105.
   PubMed Web of Science ®Google Scholar
• Benitez L, Perissinotti AJ, Santarossa M, et al. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. Pediatr Blood Cancer. 2015;62:1115.
   PubMed Web of Science ®Google Scholar
• Granger Genetics; [Internet]; [cited 2017 Mar 20] Available from: http://www.grangergenetics.com/services/asparaginase/
   Google Scholar
• Next Molecular Analytics; [Internet]; [cited 2017 Mar 20] Available from: https://www.nextmolecular.com/asparaginase
   Google Scholar
• Howard S, Szwiec K, Buddington K, et al. The weaned pig as a model for asparaginase infusion reactions. Pediatr Blood Cancer. 2015;62:S87. doi: 610.1002/pbc.25540.
   Web of Science ®Google Scholar
• Heitink-Polle KM, Prinsen BH, de Koning TJ, et al. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. JIMD Rep. 2013;7:103–108.
   PubMedGoogle Scholar
• Nussbaum V, Lubcke N, Findlay R. Hyperammonemia secondary to asparaginase: a case series. J Oncol Pharm Pract. 2016;22:161–164.
   PubMedGoogle Scholar
• Jorck C, Kiess W, Weigel JF, et al. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2011;28:3–9.
   PubMed Web of Science ®Google Scholar